Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vectorite Biomedical's enterprise value is NT$372.74 Mil.
Vectorite Biomedical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$127.62 Mil. Therefore, Vectorite Biomedical's EV-to-EBITDA for today is 2.92.
The historical rank and industry rank for Vectorite Biomedical's EV-to-EBITDA or its related term are showing as below:
ROCO:4170'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -93.9 Med: -13.55 Max: 4.78
Current: 2.92
During the past 13 years, the highest EV-to-EBITDA of Vectorite Biomedical was 4.78. The lowest was -93.90. And the median was -13.55.
ROCO:4170's EV-to-EBITDA is ranked better than 72.95% of 403
companies
in the Biotechnology industry
Industry Median: 13.7
vs ROCO:4170: 2.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vectorite Biomedical's PE Ratio (TTM) for today is calculated as:
Vectorite Biomedical's share price for today is NT$12.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectorite Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$2.701.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vectorite Biomedical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Vectorite Biomedical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's EV-to-EBITDA falls into.
Vectorite Biomedical's current Enterprise Value is NT$372.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectorite Biomedical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$127.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectorite Biomedical (ROCO:4170) has a EV-to-EBITDA of 2.92 as of Sep. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vectorite Biomedical. According to the industry distribution chart, Vectorite Biomedical ranks #109 out of 403 companies in the Biotechnology industry, placing it in the top 27%.
Is Vectorite Biomedical's EV-to-EBITDA too high?
Vectorite Biomedical's current EV-to-EBITDA is 2.92. The Biotechnology industry median EV-to-EBITDA is 13.70. Vectorite Biomedical's value of 2.92 is 78.7% below this industry median. Based on the distribution chart, Vectorite Biomedical ranks #109 out of 403 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vectorite Biomedical has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #109 out of 403 companies for EV-to-EBITDA. This puts Vectorite Biomedical in the upper half of its industry. The industry median EV-to-EBITDA is 13.70. Vectorite Biomedical's value of 2.92 is 78.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectorite Biomedical's current EV-to-EBITDA of 2.92 is 78.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vectorite Biomedical. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectorite Biomedical's current EV-to-EBITDA is 2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$13.92, compared to a current price of NT$12.30 — trading 11.6% below its estimated fair value. The current EV-to-EBITDA is 2.92 and 78.7% below the Biotechnology industry median of 13.70. Vectorite Biomedical's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current EV-to-EBITDA is 2.92 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$12.30 is trading 11.6% below its estimated GF Value™ of NT$13.92.
GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.
Key valuation signals for ROCO:4170:
EV-to-EBITDA: 2.92
GF Value™: NT$13.92 vs. price of NT$12.30 (11.6% below fair value)
Industry Position: 78.7% below the Biotechnology median (#109 of 403)
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
66GF Score
Get the complete analysis for ROCO:4170
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
